| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |